Sign in Subscribe
Pharmaceutical industry

Nexium Demonstrates Higher Healing Rates in Erosive Esophagitis Treatment

Strategic Insights

— 1 min read

A new comparative study between Prilosec (omeprazole) and Nexium (esomeprazole magnesium) has shown that the latter provides higher healing rates in the treatment of erosive esophagitis (EE). Additionally, patients receiving Nexium experienced a higher proportion of sustained heartburn resolution. This study is consistent with previous results presented at Digestive Disease Week (DDW), a large international meeting within the gastrointestinal and hepatic healthcare community. The results suggest that esomeprazole may be more effective than omeprazole in healing EE and resolving heartburn in patients with gastroesophageal reflux disease (GERD).

Key Takeaways:

  • Nexium (esomeprazole magnesium) demonstrated higher healing rates in the treatment of erosive esophagitis (EE) compared to Prilosec (omeprazole) in a study involving 1,960 patients.
  • The study found that patients receiving Nexium experienced a higher proportion of sustained heartburn resolution.
  • Esomeprazole may be more effective than omeprazole in healing EE and resolving heartburn in patients with gastroesophageal reflux disease (GERD).
  • The safety profiles of both medications were similar, with the most common adverse events being headache, abdominal pain, and diarrhea.
  • Nexium is a new chemical entity developed as an isomer from Prilosec, the first proton pump inhibitor (PPI).
  • AstraZeneca submitted a New Drug Application (NDA) for Nexium to the U.S. Food and Drug Administration (FDA) on December 3, 1999.

Statistics:

  • 1,960 patients were enrolled in the study to evaluate the efficacy of Nexium in treating erosive esophagitis (EE).
  • Patients receiving Nexium experienced a higher proportion of sustained heartburn resolution within four and eight weeks of treatment.
  • The incidence of adverse events in the study was similar for Nexium and Prilosec, with the most common events being headache (14.1%), abdominal pain (11.4%), and diarrhea (10.3%).
  • Approximately 21 million Americans may have gastroesophageal reflux disease (GERD), based on self-reported episodes of heartburn on two-or-more days a week.

Sources:

  • San Diego, May 22 /PRNewswire/- (no date provided)
  • Journal title and author not specified in the original text

Read more